| Literature DB >> 1744683 |
M J Allalunis-Turner1, R S Day, J D McKean, K C Petruk, P B Allen, K E Aronyk, B K Weir, D Huyser-Wierenga, D S Fulton, R C Urtasun.
Abstract
Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity. The average GSH concentration of biopsy specimens was lower than those of cultured cells (2.36 +/- 0.44 vs. 11.42 +/- 2.32 nmol/10(6) cells). While some of the tumor specimens were sensitive to either BCNU or HN2, the majority were resistant to both. However, 8 of 23 tumors tested showed enhanced sensitivity to BCNU following treatment with BSO. Five of 17 tumors were similarly sensitized to HN2 by BSO. These results suggest that BSO chemosensitization may be of value for certain patients and that screening assays may help identify treatment-sensitive individuals.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1744683 DOI： 10.1007/bf02390175
Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130